Eucrates Biomedical Acquisition Common Stock

Eucrates Biomedical Acquisition's common stock stands at $12M as of December 2022. That compares with $100M in the prior-year period — down 88.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Eucrates Biomedical Acquisition reported $12M in common stock versus $100M a year earlier — a 88.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $100M in the prior-year period — down 88.3% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Eucrates Biomedical Acquisition's common stock evolved across reporting periods, while the comparison chart places EUCR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.